Literature DB >> 17893112

Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.

K Rejdak1, A Petzold, Z Stelmasiak, G Giovannoni.   

Abstract

This study investigated the cerebrospinal fluid (CSF) levels of ferritin, S100B as biomarkers for glial activation and NfH(SM135)--a biomarker of axonal damage--in relation to nitric oxide (NO) metabolites: nitrate and nitrite (NOx) during acute multiple sclerosis (MS) relapse. Thirty-four relapsing-remitting MS (RR-MS) patients during acute relapse and 12 controls were enrolled. Patients were assessed on Expanded Disability Status Scale (EDSS) and underwent lumbar puncture within two weeks following relapse. Twenty patients were available for further follow-up and were assessed on EDSS 6-8 weeks since the relapse onset. The CSF NOx (P<0.0001), NfH(SM135) (P=0.01) and S100B (P=0.009) but not ferritin (P>0.05) were significantly raised in MS group. There was a significant correlation between CSF ferritin and S100B in RR-MS group (P=0.004). CSF NOx did not correlate with S100B and ferritin in study groups. RR-MS patients with detectable NfH(SM135) levels had higher NOx compared with subjects having undetectable NfH(SM135) (P=0.03). In the follow-up study, raised baseline levels of NOx (P=0.016) or NfH(SM135) (P=0.04) inversely correlated with the clinical recovery grade expressed as relative EDSS change between baseline and follow-up. In conclusion, NO metabolites were increased and because of their correlation with a biomarker of axonal degeneration (neurofilaments) and a measure for clinical disability (EDSS), relapse-related nitrosative stress is likely to be relevant to the development of sustained disability in an individual patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893112     DOI: 10.1177/1352458507082061

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  27 in total

1.  Chemotherapeutics in the treatment of multiple sclerosis.

Authors:  Bernd C Kieseier; Douglas R Jeffery
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

2.  In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes.

Authors:  S Y Yao; A Ljunggren-Rose; N Chandramohan; W O Whetsell; S Sriram
Journal:  J Neuroimmunol       Date:  2010-08-19       Impact factor: 3.478

3.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

Review 4.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

5.  The importance of nitric oxide and arginase in the pathogenesis of acute neuroinflammation: are those contra players with the same direction?

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Radmila Pavlovic; Dusica Pavlovic
Journal:  Neurotox Res       Date:  2014-04-26       Impact factor: 3.911

Review 6.  Oxidative and nitrative stress in neurodegeneration.

Authors:  Catherine A Cobb; Marsha P Cole
Journal:  Neurobiol Dis       Date:  2015-05-27       Impact factor: 5.996

7.  S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis.

Authors:  Andreia Barateiro; Vera Afonso; Gisela Santos; João José Cerqueira; Dora Brites; Jack van Horssen; Adelaide Fernandes
Journal:  Mol Neurobiol       Date:  2015-07-17       Impact factor: 5.590

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.

Authors:  Thomas Liggett; Anatoliy Melnikov; Shilpa Tilwalli; Qilong Yi; Haiyan Chen; Charles Replogle; Xuan Feng; Anthony Reder; Dusan Stefoski; Roumen Balabanov; Victor Levenson
Journal:  J Neurol Sci       Date:  2010-01-12       Impact factor: 3.181

10.  Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients.

Authors:  Giuseppe Salemi; Maria Concetta Gueli; Francesco Vitale; Floriana Battaglieri; Egidio Guglielmini; Paolo Ragonese; Angela Trentacosti; Maria Fatima Massenti; Giovanni Savettieri; Antonino Bono
Journal:  Lipids Health Dis       Date:  2010-02-18       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.